Co-expression of mesothelin and CA125/MUC16 is a prognostic factor for breast cancer, especially in luminal-type breast cancer patients

• Main Authors: Takahiro Einama (Author), Yoji Yamagishi (Author), Yasuhiro Takihata (Author), Takafumi Suzuki (Author), Tamio Yamasaki (Author), Yuichi Hirose (Author), Kazuki Kobayashi (Author), Naoto Yonamine (Author), Ibuki Fujinuma (Author), Takazumi Tsunenari (Author), Makiko Koga (Author), Yusuke Ishibashi (Author), Ken Nagata (Author), Takehiro Shiraishi (Author), Akiko Nakazawa (Author), Toshimitsu Iwasaki (Author), Eiji Shinto (Author), Kimi Kato (Author), Kimiya Sato (Author), Hideki Ueno (Author), Yoji Kishi (Author), Hitoshi Tsuda (Author)
• Format: Book
• Published: BMC, 2021-10-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract The expression of mesothelin correlates with a poor prognosis in patients with breast cancer. Since mesothelin plays a role in cancer metastasis in association with CA125, we herein examined the expression of mesothelin and CA125, and the clinicopathological meaning and prognosis of the co-...